Where Does Wall Street Think Mersana Therapeutics Inc (MRSN) Stock Will Go?

Wall Street is positive on Mersana Therapeutics Inc (MRSN). On average, analysts give Mersana Therapeutics Inc a Buy rating. The average price target is $5.285, which means analysts expect the stock to increase by 238.78% over the next twelve months. That average ranking earns Mersana Therapeutics Inc an Analyst Rating of 14, which is better than 14% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating MRSN a Buy today. Find out what this means to you and get the rest of the rankings on MRSN!

See Full MRSN Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Mersana Therapeutics Inc Stock Today?

Mersana Therapeutics Inc (MRSN) stock is up 0.97% while the S&P 500 is down -0.19% as of 1:51 PM on Thursday, Nov 16. MRSN is higher by $0.01 from the previous closing price of $1.54 on volume of 756,842 shares. Over the past year the S&P 500 has risen 13.53% while MRSN is down -76.89%. MRSN lost -$1.78 per share the over the last 12 months. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.